肺癌市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024年，全球肺癌市場規模達351億美元，預計2034年將以10.6%的複合年成長率成長，達到951億美元。這主要得益於全球肺癌發生率的上升，以及各國政府為提高公眾認知、促進早期發現和擴大治療可及性而不斷加大的力度。透過擴大援助計畫和公共衛生計畫來增加病患獲得醫療服務的機會，也為市場擴張創造了更有利的環境。隨著已開發國家老化人口的持續成長，高風險患者群體也不斷擴大，尤其是在美國、德國和日本等國家。

公共機構和私人企業加大對腫瘤學的投入，引發了藥物開發和診斷領域的創新浪潮，最終推動了市場的發展。持續的研究努力有助於發現治療肺癌的先進方法，而生物標記驅動療法的引入則促進了精準醫療的興起。憑藉這些創新，醫療保健提供者可以提供更有效、更個人化的治療方案，從而催生了對下一代診斷和治療解決方案的需求。

2024年，治療領域收入達到187億美元，因為患者和醫護人員越來越青睞標靶治療和免疫療法，而非傳統的化療。這些新的治療方案療效較佳、副作用較少，並為患者帶來更大的便利。此外，人們對聯合療法的興趣也日益濃厚，即同時使用多種治療策略，從而提高了治療方案的有效性。先進的療法如今常用於初始治療階段，這有助於重新定義各種肺癌類型的治療標準。

預計醫院癌症治療市場將大幅成長，到2034年將達到615億美元，這得益於支氣管鏡等先進診斷工具的廣泛應用，這些工具已成為醫院癌症檢測的標準配置。隨著這些工具越來越普及、效率越來越高，醫院進行的診斷程序數量也將持續成長。醫院對診斷設備和外科手術的支持性報銷框架進一步鼓勵患者到醫院就診，從而推動收入成長。

由於診斷技術的快速發展和監管機構的大力支持，美國肺癌市場在2024年的價值達到154億美元。領先的生物製藥公司和癌症研究機構的存在，加上聯邦機構的大量資金投入，推動了臨床開發和快速產品批准。這些因素為創新肺癌解決方案的採用創造了有利環境，進一步增強了北美市場的表現。

塑造全球肺癌市場格局的關鍵參與者包括默克、太陽製藥、輝瑞、羅氏、百時美施貴寶、AdvaCare Pharma、克利夫蘭診所、威爾康奈爾醫學院、羅格斯大學健康中心、Biodesix、紀念斯隆凱特琳癌症中心、梯瓦製藥、CHEPLAPHARM 集團和匹茲堡大學醫學中心。為了鞏固市場地位，各公司優先投資精準腫瘤學研究、拓展全球分銷網路，並與生技公司和學術機構建立策略合作。許多公司也正在加速臨床試驗管線的建設，以便更快推出創新療法。此外，他們也正在收購擁有有前景的候選藥物的小型公司，同時最佳化藥物輸送系統以改善患者治療效果。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 全球肺癌發生率上升
    • 診斷和篩檢技術的進步
    • 標靶療法和免疫療法的應用日益增多
    • 微創手術需求不斷成長
  • 產業陷阱與挑戰
    • 治療費用高昂
    • 缺乏技術精湛、訓練有素的腫瘤科醫生和放射科醫生
• 成長潛力分析
• 監管格局
• 川普政府關稅
  • 對貿易的影響
    • 貿易量中斷
    • 報復措施
  • 對產業的影響
    • 供給側影響（原料）
      • 主要材料價格波動
      • 供應鏈重組
      • 生產成本影響
    • 需求面影響（售價）
      • 價格傳導至終端市場
      • 市佔率動態
      • 消費者反應模式
  • 受影響的主要公司
  • 策略產業反應
    • 供應鏈重組
    • 定價和產品策略
    • 政策參與
  • 展望與未來考慮
• 未來市場趨勢
• 肺癌流行病學
• 報銷場景
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按診斷和治療，2021 年至 2034 年

• 主要趨勢
• 診斷
  • 支氣管鏡檢查
  • 分子檢測
  • 影像學
  • 其他診斷
• 療法
  • 非侵入性治療
    • 按類型
      • 化療
      • 標靶治療
      • 免疫療法
      • 其他非侵入性療法
    • 依給藥途徑
      • 口服
      • 腸外
  • 微創治療
    • 射頻消融
    • 微波消融
    • 熱/冷凍消融
    • 其他微創療法

第6章：市場估計與預測：按適應症，2021 年至 2034 年

• 主要趨勢
• 非小細胞肺癌
• 小細胞肺癌

第7章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 醫院
• 診斷實驗室
• 專科診所
• 其他最終用途

第8章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• AdvaCare Pharma
• Biodesix
• Bristol-Myers Squibb Company
• CHEPLAPHARM Group
• Cleveland Clinic
• F. Hoffmann La Roche
• Memorial Sloan Kettering Cancer Center
• Merck & Co.
• Pfizer
• Rutgers Health Sun Pharmaceutical
• Sun Pharmaceuticals
• Teva Pharmaceuticals
• UPMC
• Weill Cornell Medicine

The Global Lung Cancer Market was valued at USD 35.1 billion in 2024 and is estimated to grow at a CAGR of 10.6% to reach USD 95.1 billion by 2034, driven by the rising incidence of lung cancer worldwide, as well as growing government efforts to improve awareness, promote early detection, and enhance access to treatment. Increasing patient access to care through expanding assistance programs and public health initiatives has also contributed to a more favorable environment for market expansion. As aging populations in developed countries continue to rise, so does the at-risk patient pool, particularly in nations like the United States, Germany, and Japan.

Greater investment in oncology by public institutions and private players has triggered a wave of innovation in drug development and diagnostics, ultimately pushing the market forward. Continuous research efforts are helping to uncover advanced methods of treating lung cancer, and the introduction of biomarker-driven therapies has supported the emergence of precision medicine. With these innovations, healthcare providers can offer more effective, customized treatment regimens, creating demand for next-generation diagnostic and therapeutic solutions.

The therapeutics segment generated USD 18.7 billion in 2024, as patients and healthcare professionals increasingly prefer targeted therapies and immunotherapies over conventional chemotherapy. These new treatment options offer better outcomes, fewer side effects, and greater patient convenience. There is also growing interest in combination approaches-using multiple therapeutic strategies simultaneously, which has enhanced the effectiveness of treatment protocols. Advanced therapies are now often used in initial treatment stages, which is helping to redefine standards of care across various lung cancer types.

The hospital segment is projected to grow significantly, reaching an estimated USD 61.5 billion by 2034, fueled by the widespread adoption of advanced diagnostic tools such as bronchoscopy and other cutting-edge technologies, which have become standard in hospital settings for cancer detection. As these tools become more accessible and efficient, the number of diagnostic procedures performed in hospitals continues to rise. Supportive reimbursement frameworks for diagnostic equipment and surgical treatments in hospitals further encourage patients to seek care in these facilities, driving revenue growth.

United States Lung Cancer Market was valued at USD 15.4 billion in 2024, supported by rapid advancements in diagnostic technologies and strong support from regulatory authorities. The presence of leading biopharmaceutical companies and cancer research institutions, coupled with extensive funding from federal agencies, has fueled clinical development and fast-tracked product approvals. These elements have created a favorable landscape for the adoption of innovative lung cancer solutions, further strengthening market performance across North America.

Key players shaping the Global Lung Cancer Market landscape include Merck, Sun Pharmaceuticals, Pfizer, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, AdvaCare Pharma, Cleveland Clinic, Weill Cornell Medicine, Rutgers Health, Biodesix, Memorial Sloan Kettering Cancer Center, Teva Pharmaceuticals, CHEPLAPHARM Group, and UPMC. To strengthen their market presence, companies prioritize investing in precision oncology research, expanding global distribution networks, and forming strategic collaborations with biotech firms and academic institutions. Many are also accelerating their clinical trial pipelines to introduce innovative therapies faster. Additionally, they are acquiring smaller firms with promising drug candidates, while optimizing drug delivery systems to improve patient outcomes.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of lung cancer globally
    • 3.2.1.2 Technology advancements in diagnostics and screening
    • 3.2.1.3 Increasing adoption of targeted and immune therapies
    • 3.2.1.4 Rising demand for minimally invasive procedures
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Dearth of well-skilled and trained oncologists and radiologists
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the Industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Future market trends
• 3.7 Lung cancer epidemiology
• 3.8 Reimbursement scenario
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Diagnostics and Therapeutics, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Diagnostics
  • 5.2.1 Bronchoscopy
  • 5.2.2 Molecular testing
  • 5.2.3 Imaging
  • 5.2.4 Other diagnostics
• 5.3 Therapeutics
  • 5.3.1 Non-invasive therapy
    • 5.3.1.1 By type
      • 5.3.1.1.1 Chemotherapy
      • 5.3.1.1.2 Targeted therapy
      • 5.3.1.1.3 Immunotherapy
      • 5.3.1.1.4 Other non-invasive therapies
    • 5.3.1.2 By route of administration
      • 5.3.1.2.1 Oral
      • 5.3.1.2.2 Parenteral
  • 5.3.2 Minimally invasive therapy
    • 5.3.2.1 Radiofrequency ablation
    • 5.3.2.2 Microwave ablation
    • 5.3.2.3 Thermal/cryoablation
    • 5.3.2.4 Other minimally invasive therapies

Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Non-small cell lung cancer
• 6.3 Small cell lung cancer

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Diagnostic laboratories
• 7.4 Specialty clinics
• 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AdvaCare Pharma
• 9.2 Biodesix
• 9.3 Bristol-Myers Squibb Company
• 9.4 CHEPLAPHARM Group
• 9.5 Cleveland Clinic
• 9.6 F. Hoffmann La Roche
• 9.7 Memorial Sloan Kettering Cancer Center
• 9.8 Merck & Co.
• 9.9 Pfizer
• 9.10 Rutgers Health Sun Pharmaceutical
• 9.11 Sun Pharmaceuticals
• 9.12 Teva Pharmaceuticals
• 9.13 UPMC
• 9.14 Weill Cornell Medicine